Cargando…

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

BACKGROUND: Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients with rheumatoid arthritis (RA). Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor and is approved for the treatment of moderately to severely active RA in adults in over 50 countries incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winthrop, Kevin L., Bingham, Clifton O., Komocsar, Wendy J., Bradley, John, Issa, Maher, Klar, Rena, Kartman, Cynthia E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471863/ https://www.ncbi.nlm.nih.gov/pubmed/30999933 http://dx.doi.org/10.1186/s13075-019-1883-1

Ejemplares similares

BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis
por: Bingham, Clifton O., et al.
Publicado: (2015)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
por: Alten, Rieke, et al.
Publicado: (2016)

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
por: Taylor, Peter C, et al.
Publicado: (2022)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2016)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
por: Winthrop, Kevin, et al.
Publicado: (2022)

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials
por: Sholter, Dalton, et al.
Publicado: (2022)

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy
por: Mori, Shunsuke, et al.
Publicado: (2013)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Forcible Extension of Nerves in Traumatic Tetanus
Publicado: (1877)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
por: Koumaki, Dimitra, et al.
Publicado: (2019)

Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants
por: Gomez, Elisa V., et al.
Publicado: (2017)

Pneumococcal-vaccine/tetanus-vaccine/tozinameran: Exacerbation of AQP4 antibody positive acute longitudinal extensive transverse myelitis: case report
Publicado: (2022)

LB3. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomized, Placebo-Controlled Trial
por: Ely, E Wesley, et al.
Publicado: (2021)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report
por: Kaneko, Yutaka, et al.
Publicado: (2022)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2023)

The Immunogenicity of the C Fragment of Tetanus Neurotoxin in Production of Tetanus Antitoxin
por: Yu, Rui, et al.
Publicado: (2018)

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
por: Bieber, Thomas, et al.
Publicado: (2022)

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
por: Ely, E Wesley, et al.
Publicado: (2022)

Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes
por: Tucci, Gloria, et al.
Publicado: (2022)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
por: Bieber, Thomas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ij1jb6t7mo5cemissmc6tci0ji